Cognition Therapeutics Stock Alpha and Beta Analysis
| CGTX Stock | USD 0.42 0.03 6.67% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Cognition Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Cognition Therapeutics over a specified time horizon. Remember, high Cognition Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Cognition Therapeutics' market risk premium analysis include:
Beta 1.96 | Alpha (0.38) | Risk 4.5 | Sharpe Ratio (0.18) | Expected Return (0.83) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Cognition |
Cognition Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Cognition Therapeutics market risk premium is the additional return an investor will receive from holding Cognition Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Cognition Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Cognition Therapeutics' performance over market.| α | -0.38 | β | 1.96 |
Cognition Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Cognition Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Cognition Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Cognition Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Cognition Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Cognition Therapeutics shares will generate the highest return on investment. By understating and applying Cognition Therapeutics stock market price indicators, traders can identify Cognition Therapeutics position entry and exit signals to maximize returns.
Cognition Therapeutics Return and Market Media
The median price of Cognition Therapeutics for the period between Mon, Dec 30, 2024 and Sun, Mar 30, 2025 is 0.61 with a coefficient of variation of 22.74. The daily time series for the period is distributed with a sample standard deviation of 0.14, arithmetic mean of 0.6, and mean deviation of 0.12. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Acquisition by Fletcher Aaron G.l. of 500095 shares of Cognition Therapeutics at 1.05 subject to Rule 16b-3 | 01/23/2025 |
2 | Cognition Therapeutics Rating Increased to Strong-Buy at Brookline Capital Management | 01/28/2025 |
3 | Acquisition by Lisa Ricciardi of 38851 shares of Cognition Therapeutics at 0.7722 subject to Rule 16b-3 | 01/31/2025 |
4 | Disposition of 28960 shares by Lisa Ricciardi of Cognition Therapeutics at 0.666 subject to Rule 16b-3 | 02/03/2025 |
5 | Acquisition by Lisa Ricciardi of 631300 shares of Cognition Therapeutics subject to Rule 16b-3 | 02/04/2025 |
6 | Disposition of 1723 shares by John Doyle of Cognition Therapeutics at 0.5901 subject to Rule 16b-3 | 02/14/2025 |
7 | Cognition Therapeutics Announces Publication of Commercial ManufacturingProcess for Lead Alzheimers Candidate, Zervimesine | 02/20/2025 |
8 | Disposition of 2469 shares by Fletcher Aaron G.l. of Cognition Therapeutics at 1.92 subject to Rule 16b-3 | 02/21/2025 |
9 | Cognition Therapeutics VP of Research Co-hosting Precision Medicine Workshop at the Neuroimmunology Drug Development Summit | 02/25/2025 |
10 | Cognition Therapeutics Successfully Passes Pre-defined Futility Analysis of Phase 2 Study of Oral Zervimesine in Geographic Atrophy | 02/26/2025 |
11 | Acquisition by Kreis Leslie W. of 6000 shares of Cognition Therapeutics at 2.77 subject to Rule 16b-3 | 03/05/2025 |
12 | Cognition Therapeutics Granted Extension to Meet Nasdaq Minimum Bid Price Requirement for Continued Exchange Listing | 03/12/2025 |
13 | Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update | 03/20/2025 |
14 | Q4 2024 Cognition Therapeutics Inc Earnings Call Transcript | 03/21/2025 |
15 | Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate ... | 03/25/2025 |
16 | Equities Analysts Offer Predictions for CGTX Q1 Earnings | 03/26/2025 |
About Cognition Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Cognition or other stocks. Alpha measures the amount that position in Cognition Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2024 | 2025 (projected) | |
| Payables Turnover | 0.0614 | 0.0395 |
| Days Of Inventory On Hand | 7.0K | 7.4K |
Cognition Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Cognition Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cognition Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Cognition Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Cognition Therapeutics. Please utilize our Beneish M Score to check the likelihood of Cognition Therapeutics' management manipulating its earnings.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Cognition Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Cognition Stock Analysis
When running Cognition Therapeutics' price analysis, check to measure Cognition Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cognition Therapeutics is operating at the current time. Most of Cognition Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cognition Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cognition Therapeutics' price. Additionally, you may evaluate how the addition of Cognition Therapeutics to your portfolios can decrease your overall portfolio volatility.